Study: Psoriasis drug boosts insulin secretion in type 1 diabetes

09/23/2013 | DailyRx.com

Type 1 diabetes patients who received the psoriasis medication alefacept attained significant improvements in preserved insulin secretion at four hours compared with those in the placebo group, according to a study in The Lancet Diabetes & Endocrinology. Researchers also found patients in the alefacept arm were using less supplementary insulin and were less likely than those in the control group to experience hypoglycemic episodes one year after starting treatment.

View Full Article in:

DailyRx.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN